New treatment paradigm for patients with anaplastic oligodendroglial tumors.
Anticancer Res
; 34(4): 1587-94, 2014 Apr.
Article
in En
| MEDLINE
| ID: mdl-24692686
ABSTRACT
Oligodendrogliomas are uncommon tumors in neurooncology that represent about 5% of primary brain malignancies. Their high sensitivity to radiotherapy and chemotherapy was observed a long time ago. Nonetheless, the evidence-based proof of the significantly longer survival in patients with oligodendrogliomas treated with combined chemotherapy and radiotherapy in comparison to radiotherapy-alone did not exist. The long-term follow-up of two landmark phase III clinical trials RTOG 9402 and EORTC 26951, recently demonstrated favorable effects of combined radiotherapy and chemotherapy (procarbazine, lomustine and vincristine) in patients with anaplastic oligodendrogliomas and anaplastic oligoastrocytomas carrying the chromosomal mutation of co-deletion of 1p/19q. There is also an increasing role of other molecular biomarkers, such as mutations in the metabolic enzyme isocitrate dehydrogenase 1/2, O6-methylguanine DNA methyltransferase gene promoter methylation, or glioma genome cytosine-phosphate-guanine islands methylator phenotype. The analysis of molecular genetics in oligodendrogliomas is now recommended as an important part of the management of these tumors and together with the novel chemotherapeutic regimens means a paradigm shift in current clinical practice in neurooncology.
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oligodendroglioma
/
Brain Neoplasms
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Anticancer Res
Year:
2014
Type:
Article
Affiliation country:
Czech Republic